TY  - JOUR
AU  - Duque, Natalia
AU  - Artime, Esther
AU  - Romera, Irene
AU  - Lebrec, Jeremie
AU  - Díaz, Silvia
AU  - Rubio, Miriam
AU  - Sicras-Mainar, Antoni
AU  - Carretero-Anibarro, Enrique
AU  - Mundet, Xavier
AU  - Gorgojo-Martínez, Juan J
AU  - Reviriego, Jesús
PY  - 2021
DO  - 10.1007/s12325-021-01773-z
UR  - http://hdl.handle.net/10668/17850
T2  - Advances in therapy
AB  - In the EDITION clinical trial programme, patients with type 2 diabetes mellitus (T2DM) receiving insulin glargine (IGlar) U300 required 10-15% more insulin than those receiving IGlar U100. This study sought to determine whether this difference was...
LA  - en
KW  - Cost
KW  - Dose
KW  - Glycaemic control
KW  - Insulin glargine
KW  - Real-world evidence
KW  - Type 2 diabetes mellitus
KW  - U100
KW  - U300
KW  - Adult
KW  - Blood Glucose
KW  - Diabetes Mellitus, Type 2
KW  - Female
KW  - Glycated Hemoglobin
KW  - Humans
KW  - Hypoglycemic Agents
KW  - Insulin
KW  - Insulin Glargine
KW  - Male
KW  - Middle Aged
KW  - Retrospective Studies
KW  - Spain
TI  - Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: DosInGlar Study.
TY  - research article
VL  - 38
ER  -